Seymour L, Nuru N, Johnson K, Gutierrez J, Njoku V, Darie C
Molecules. 2025; 30(3).
PMID: 39942749
PMC: 11820228.
DOI: 10.3390/molecules30030645.
Iggo R, MacGrogan G
Adv Exp Med Biol. 2025; 1464():185-207.
PMID: 39821027
DOI: 10.1007/978-3-031-70875-6_11.
Van Keymeulen A
Adv Exp Med Biol. 2025; 1464():167-184.
PMID: 39821026
DOI: 10.1007/978-3-031-70875-6_10.
Bacha R, Alwisi N, Ismail R, Pedersen S, Al-Mansoori L
Cells. 2025; 13(24.
PMID: 39768217
PMC: 11674286.
DOI: 10.3390/cells13242127.
Sayaman R, Miyano M, Carlson E, Senapati P, Zirbes A, Shalabi S
Elife. 2024; 13.
PMID: 39545637
PMC: 11723586.
DOI: 10.7554/eLife.95720.
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages.
Iglesia M, Jayasinghe R, Chen S, Terekhanova N, Herndon J, Storrs E
Nat Cancer. 2024; 5(11):1713-1736.
PMID: 39478117
PMC: 11584403.
DOI: 10.1038/s43018-024-00773-6.
Bioinformatic and experimental analyses of GATA3 and its regulatory miRNAs in breast Cancer.
Roohy F, Moghanibashi M, Tahmasebi S
Discov Oncol. 2024; 15(1):588.
PMID: 39448444
PMC: 11502614.
DOI: 10.1007/s12672-024-01479-y.
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution.
Schade A, Perurena N, Yang Y, Rodriguez C, Krishnan A, Gardner A
Nature. 2024; 635(8039):755-763.
PMID: 39385030
PMC: 11578877.
DOI: 10.1038/s41586-024-08031-6.
Enhancer landscape of lung neuroendocrine tumors reveals regulatory and developmental signatures with potential theranostic implications.
Davis E, Avniel-Polak S, Abu-Kamel S, Antman I, Saadoun T, Brim C
Proc Natl Acad Sci U S A. 2024; 121(41):e2405001121.
PMID: 39361648
PMC: 11474083.
DOI: 10.1073/pnas.2405001121.
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer.
Sandstrom J, Bomanson J, Perez-Tenorio G, Jonsson C, Nordenskjold B, Fornander T
NPJ Breast Cancer. 2024; 10(1):78.
PMID: 39242600
PMC: 11379893.
DOI: 10.1038/s41523-024-00688-6.
Progesterone receptor is constitutively expressed in induced Pluripotent Stem Cells (iPSCs).
Manganelli M, Mazzoldi E, Ferraro R, Pinelli M, Parigi M, Aghel S
Stem Cell Rev Rep. 2024; 20(8):2303-2317.
PMID: 39168923
PMC: 11554879.
DOI: 10.1007/s12015-024-10776-6.
Increased prevalence of hybrid epithelial/mesenchymal state and enhanced phenotypic heterogeneity in basal breast cancer.
Sahoo S, Ramu S, Nair M, Pillai M, San Juan B, Milioli H
iScience. 2024; 27(7):110116.
PMID: 38974967
PMC: 11225361.
DOI: 10.1016/j.isci.2024.110116.
Adipo-Epithelial Transdifferentiation in In Vitro Models of the Mammary Gland.
Perugini J, Smorlesi A, Acciarini S, Mondini E, Colleluori G, Pirazzini C
Cells. 2024; 13(11.
PMID: 38891075
PMC: 11171678.
DOI: 10.3390/cells13110943.
TRPS1 maintains luminal progenitors in the mammary gland by repressing SRF/MRTF activity.
Tollot-Wegner M, Jessen M, Kim K, Sanz-Moreno A, Spielmann N, Gailus-Durner V
Breast Cancer Res. 2024; 26(1):74.
PMID: 38702730
PMC: 11067134.
DOI: 10.1186/s13058-024-01824-7.
GATA3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in breast cancer.
Wang X, Bai F, Liu X, Peng B, Xu X, Zhang H
BMC Biol. 2024; 22(1):85.
PMID: 38627785
PMC: 11020915.
DOI: 10.1186/s12915-024-01881-6.
ERG activates a stem-like proliferation-differentiation program in prostate epithelial cells with mixed basal-luminal identity.
Feng W, Ladewig E, Salsabeel N, Zhao H, Lee Y, Gopalan A
bioRxiv. 2024; .
PMID: 38585869
PMC: 10996491.
DOI: 10.1101/2023.05.15.540839.
Predicting transcription factor activity using prior biological information.
Yashar W, Estabrook J, Holly H, Somers J, Nikolova O, Babur O
iScience. 2024; 27(3):109124.
PMID: 38455978
PMC: 10918219.
DOI: 10.1016/j.isci.2024.109124.
A Metabolic-Epigenetic Mechanism Directs Cell Fate and Therapeutic Sensitivity in Breast Cancer.
Bernard M, Goldstein A
Cancer Res. 2024; 84(9):1382-1383.
PMID: 38330100
PMC: 11065557.
DOI: 10.1158/0008-5472.CAN-24-0460.
The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer.
Hosseinzadeh L, Kikhtyak Z, Laven-Law G, Pederson S, Puiu C, DSantos C
Genome Biol. 2024; 25(1):44.
PMID: 38317241
PMC: 10840202.
DOI: 10.1186/s13059-023-03161-y.
Two Faces of Glutaminase GLS2 in Carcinogenesis.
Buczkowska J, Szeliga M
Cancers (Basel). 2023; 15(23).
PMID: 38067269
PMC: 10705333.
DOI: 10.3390/cancers15235566.